Recent Material Events - Nutra Pharma Corp (NPHC)

Filing Date	Description
2008-11-17	Material event, click here to read
2008-08-13	If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate) ...
2008-05-16	If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate) ...
2008-04-15	Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). YES o NO x ...
2008-04-14	The following tables sets forth, as of March 31, 2008, certain information with respect to the beneficial ownership of our common stock by each stockholder known by us to be the beneficial owner of more than 5% of our common stock and by each of ...
2008-04-14	From June 2001 to present, Paul F. Reid, PhD has been the Chief Executive Officer of ReceptoPharm, Inc., a biotechnology company located Plantation, Florida. From August 1996 to April 2001, Dr. Reid was the Head of Scientific Affairs for Biothe ...
2008-03-18	Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized. ...
2006-04-07	On April 1, 2006, our Board of Directors unanimously approved the reappointment of Rik Deitsch as our Chairman of the Board.... ...
2005-11-10	Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this current report to be signed on its behalf by the undersigned hereunto duly authorized.... ...
2005-06-06	Michael Flax resigned as a director of the Company on June 1, 2005. Rik J. Deitsch resigned as the Company’s Chairman on June 1, 2005. Mr. Deitsch will continue to serve as a director of the Company and as the Company’s President and Chi... ...